View Future GrowthAmicogen 과거 순이익 실적과거 기준 점검 0/6Amicogen 의 수입은 연평균 -46.3%의 비율로 감소해 온 반면, Biotechs 산업은 연평균 18.6%의 비율로 증가했습니다. 매출은 연평균 0.6%의 비율로 감소해 왔습니다.핵심 정보-46.28%순이익 성장률-42.50%주당순이익(EPS) 성장률Biotechs 산업 성장률11.70%매출 성장률-0.64%자기자본이익률-28.51%순이익률-71.36%최근 순이익 업데이트31 Dec 2025최근 과거 실적 업데이트Reported Earnings • Mar 25Full year 2024 earnings released: ₩961 loss per share (vs ₩584 loss in FY 2023)Full year 2024 results: ₩961 loss per share (further deteriorated from ₩584 loss in FY 2023). Revenue: ₩173.6b (up 8.6% from FY 2023). Net loss: ₩52.8b (loss widened 127% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 11% per year but the company’s share price has fallen by 38% per year, which means it is performing significantly worse than earnings.분석 기사 • Dec 30Amicogen (KOSDAQ:092040) Is Growing Earnings But Are They A Good Guide?Statistically speaking, it is less risky to invest in profitable companies than in unprofitable ones. However...모든 업데이트 보기Recent updates공시 • Mar 11Amicogen, Inc., Annual General Meeting, Mar 31, 2026Amicogen, Inc., Annual General Meeting, Mar 31, 2026, at 10:00 Tokyo Standard Time. Location: conference room, 33, yeongudanji-ro 55beon-gil, yeonsu-gu, incheon South KoreaNew Risk • Feb 26New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 29% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (14% average weekly change). Earnings have declined by 52% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (29% increase in shares outstanding). Market cap is less than US$100m (₩87.7b market cap, or US$61.5m).New Risk • Feb 24New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 14% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (14% average weekly change). Earnings have declined by 52% per year over the past 5 years. Minor Risk Market cap is less than US$100m (₩69.6b market cap, or US$48.2m).공시 • Feb 10Amicogen, Inc. has completed a Follow-on Equity Offering in the amount of KRW 17.373135 billion.Amicogen, Inc. has completed a Follow-on Equity Offering in the amount of KRW 17.373135 billion. Security Name: Common Stock Security Type: Common Stock Securities Offered: 14,925,374 Price\Range: KRW 1164분석 기사 • Dec 22Investors Don't See Light At End Of Amicogen, Inc.'s (KOSDAQ:092040) Tunnel And Push Stock Down 33%Unfortunately for some shareholders, the Amicogen, Inc. ( KOSDAQ:092040 ) share price has dived 33% in the last thirty...New Risk • Dec 22New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 52% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Market cap is less than US$100m (₩108.0b market cap, or US$73.0m).공시 • Dec 20Amicogen, Inc. has filed a Follow-on Equity Offering in the amount of KRW 30.000002 billion.Amicogen, Inc. has filed a Follow-on Equity Offering in the amount of KRW 30.000002 billion. Security Name: Common Stock Security Type: Common Stock Securities Offered: 14,925,374 Price\Range: KRW 2010New Risk • Dec 02New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩143.8b (US$97.9m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩44b free cash flow). Earnings have declined by 52% per year over the past 5 years. Minor Risk Market cap is less than US$100m (₩143.8b market cap, or US$97.9m).New Risk • Nov 29New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₩44b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩44b free cash flow). Earnings have declined by 52% per year over the past 5 years.분석 기사 • Sep 08The Market Doesn't Like What It Sees From Amicogen, Inc.'s (KOSDAQ:092040) Revenues YetWith a price-to-sales (or "P/S") ratio of 1.8x Amicogen, Inc. ( KOSDAQ:092040 ) may be sending very bullish signals at...공시 • Aug 12Amicogen, Inc. announced that it has received KRW 7 billion in funding from BIFIDO Co., Ltd.On August 11, 2025, Amicogen, Inc. closed the transaction.New Risk • Jul 17New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩25b free cash flow). Share price has been highly volatile over the past 3 months (12% average weekly change). Earnings have declined by 46% per year over the past 5 years.분석 기사 • May 23Amicogen, Inc.'s (KOSDAQ:092040) Share Price Is Matching Sentiment Around Its RevenuesYou may think that with a price-to-sales (or "P/S") ratio of 1.3x Amicogen, Inc. ( KOSDAQ:092040 ) is definitely a...Reported Earnings • Mar 25Full year 2024 earnings released: ₩961 loss per share (vs ₩584 loss in FY 2023)Full year 2024 results: ₩961 loss per share (further deteriorated from ₩584 loss in FY 2023). Revenue: ₩173.6b (up 8.6% from FY 2023). Net loss: ₩52.8b (loss widened 127% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 11% per year but the company’s share price has fallen by 38% per year, which means it is performing significantly worse than earnings.공시 • Mar 12Amicogen, Inc., Annual General Meeting, Mar 27, 2025Amicogen, Inc., Annual General Meeting, Mar 27, 2025, at 10:00 Tokyo Standard Time. Location: conference room, 33, yeongudanji-ro 55beon-gil, yeonsu-gu, incheon South Korea분석 기사 • Feb 17Is Amicogen (KOSDAQ:092040) Using Too Much Debt?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...분석 기사 • Jan 08Amicogen, Inc. (KOSDAQ:092040) Held Back By Insufficient Growth Even After Shares Climb 35%Amicogen, Inc. ( KOSDAQ:092040 ) shareholders are no doubt pleased to see that the share price has bounced 35% in the...New Risk • Dec 23New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (3.7% operating cash flow to total debt). Earnings have declined by 44% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (9.4% average weekly change). Shareholders have been diluted in the past year (40% increase in shares outstanding).공시 • Dec 12An undisclosed buyer agreed to acquire an unknown stake in Amicogen (China) Biopharm Co., Ltd. from Amicogen, Inc. (KOSDAQ:A092040) for KRW 54.7 billion.An undisclosed buyer agreed to acquire an unknown stake in Amicogen (China) Biopharm Co., Ltd. from Amicogen, Inc. (KOSDAQ:A092040) for KRW 54.7 billion on December 10, 2024. After completion of this ransaction, Amicogen, Inc. will hold 14.36% stake in Amicogen (China) Biopharm. Amicogen (China) Biopharm reported total assets of KRW 210.359 billion, total debt of KRW 95.656 billion, sales of KRW 84.911 billion and net income of KRW 8.074 billion as at September 30, 2024. The expected completion of the transaction is December 30, 2024.New Risk • Dec 09New major risk - Financial positionThe company's debt is not well covered by operating cash flow. Operating cash flow to total debt ratio: 3.7% This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (3.7% operating cash flow to total debt). Earnings have declined by 44% per year over the past 5 years. Minor Risk Shareholders have been diluted in the past year (40% increase in shares outstanding).New Risk • Dec 07New minor risk - Financial data availabilityLess than 3 years of financial data is available. This is considered a minor risk. If the company has been trading for less than 3 years, then it has not had the opportunity to establish a long-term track record. This makes it difficult for investors to assess the true growth potential, sustainability and resilience of the business under different economic conditions. Currently, the following risks have been identified for the company: Minor Risks Less than 3 years of financial data is available. Shareholders have been diluted in the past year (40% increase in shares outstanding).공시 • Nov 23Enzynomics Co., Ltd. completed the acquisition of 37.32% stake in SKINMED Co., Ltd. from Amicogen, Inc. (KOSDAQ:A092040).Enzynomics Co., Ltd. agreed to acquire 37.32% stake in SKINMED Co., Ltd. from Amicogen, Inc. (KOSDAQ:A092040) for KRW 5.6 billion on November 15, 2024. A cash consideration of KRW 5.6 billion will be paid by Enzynomics for 2,360,714 shares. For the period ending December 31, 2023, SKINMED Co., Ltd. reported total revenue of KRW 6.07 billion and net loss of KRW 1.04 billion. As of December 31, 2023, SKINMED Co., Ltd. reported total debt of KRW 4.96 billion, total assets of KRW 11.22 billion and total common equity of KRW 6.26 billion. Enzynomics Co., Ltd. completed the acquisition of 37.32% stake in SKINMED Co., Ltd. from Amicogen, Inc. (KOSDAQ:A092040) on November 19, 2024.분석 기사 • Nov 11Revenues Working Against Amicogen, Inc.'s (KOSDAQ:092040) Share PriceAmicogen, Inc.'s ( KOSDAQ:092040 ) price-to-sales (or "P/S") ratio of 1.5x might make it look like a strong buy right...공시 • Oct 30+ 1 more updateAmicogen, Inc. announced that it has received KRW 4 billion in funding from Kiwoom Securities Co., Ltd.On October 29, 2024 Amicogen, Inc. closed the transaction.New Risk • Sep 17New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Shareholders have been diluted in the past year (40% increase in shares outstanding).분석 기사 • Jun 27Little Excitement Around Amicogen, Inc.'s (KOSDAQ:092040) Revenues As Shares Take 27% PoundingTo the annoyance of some shareholders, Amicogen, Inc. ( KOSDAQ:092040 ) shares are down a considerable 27% in the last...분석 기사 • Jun 19Does Amicogen (KOSDAQ:092040) Have A Healthy Balance Sheet?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...분석 기사 • Mar 21Amicogen, Inc. (KOSDAQ:092040) Held Back By Insufficient Growth Even After Shares Climb 39%Amicogen, Inc. ( KOSDAQ:092040 ) shares have had a really impressive month, gaining 39% after a shaky period...New Risk • Mar 21New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (0.1x net interest cover). Earnings have declined by 48% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (8.3% average weekly change). Shareholders have been diluted in the past year (39% increase in shares outstanding).New Risk • Dec 28New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 39% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (0.1x net interest cover). Earnings have declined by 48% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (8.7% average weekly change). Shareholders have been diluted in the past year (39% increase in shares outstanding).New Risk • Nov 24New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). Earnings have declined by 44% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (8.6% average weekly change).공시 • Jul 19+ 1 more updateAmicogen, Inc. announced that it expects to receive KRW 40 billion in fundingAmicogen, Inc. announced a private placement of series 3 unregistered nonguaranteed private convertible bond for gross proceeds of KRW 40,000,000,000 on July 18, 2022. The bonds will mature on July 20, 2027. The bonds are convertible into 1,622,520 common shares at a price of KRW 24,653 per share. The conversion period is from July 20, 2023 to June 20, 2027. The payment date is July 20, 2022. The transaction has been approved by the board of directors.Valuation Update With 7 Day Price Move • Jan 27Investor sentiment deteriorated over the past weekAfter last week's 15% share price decline to ₩24,850, the stock trades at a trailing P/E ratio of 14.6x. Average trailing P/E is 33x in the Biotechs industry in South Korea. Total loss to shareholders of 34% over the past three years.공시 • Sep 03Amicogen, Inc. announced that it has received KRW 22.2724863 billion in funding from Lysando AGOn September 2, 2021, Amicogen, Inc. closed the transaction.공시 • Jul 23Amicogen, Inc. (KOSDAQ:A092040) agreed to acquire a 30% stake in BIFIDO Co., Ltd (KOSDAQ:A238200) from a group of shareholders for KRW 60.1 billion.Amicogen, Inc. (KOSDAQ:A092040) agreed to acquire a 30% stake in BIFIDO Co., Ltd (KOSDAQ:A238200) from a group of shareholders for KRW 60.1 billion on July 21, 2021. Under the term, Amicogen will acquire 2.45 million shares of BIFIDO at KRW 24,500 per shares. Amicogen will pay 20% of the consideration amounting to KRW 12.02 billion on July 21, 2021 as the down payment or first payment, second payment or the interim payment which is 30% of the consideration amounting to KRW 18.04 billion will be paid on August 20, 2021 and the balance which is 50% of the consideration amounting to KRW 30.06 billion will be paid on October 20, 2021. Post completion, Amicogen will hold 30% stake in BIFIDO. The transaction was resolved by the board of directors of Amicogen on July 21, 2021. The transaction is expected to close on October 21, 2021.공시 • Jul 15Amicogen, Inc. announced that it expects to receive KRW 22.2724863 billion in funding from Lysando AGAmicogen, Inc. announced a private placement of 532,198 shares at a price of KRW 41,850 per share for gross proceeds of KRW 22,272,486,300 on July 14, 2021. The transaction will include participation from Lysando AG. The transaction is expected to close on August 20, 2021. The securities to be issued will have a hold period of 1 year. The transaction was approved by the board of directors of the company. The company will received funding through third party allocation.공시 • Jul 01Amicogen, Inc. announced that it has received KRW 50 billion in fundingOn June 29, 2021, Amicogen, Inc. closed the transaction.공시 • Jun 24Amicogen, Inc. announced that it expects to receive KRW 50 billion in funding from Samsung Securities Co., Ltd. and other investorsAmicogen, Inc. (KOSDAQ:A092040) announced a private placement of series 1 unregistered nonguaranteed private convertible bond for gross proceeds of KRW 50,000,000,000 on June 23, 2021. The transaction will include participation from Samsung Securities Co., Ltd. (KOSE:A016360) for KRW 46,000,000,000, and Small and Medium Business Banks for the rest. The bonds will mature on June 28, 2026. The bonds are convertible into 1,203,311 common shares at a price of KRW 41,552 per share. The conversion period is from June 29, 2022 to May 29, 2026. The payment date is June 29, 2021. The transaction has been approved by the board.분석 기사 • Mar 23With EPS Growth And More, Amicogen (KOSDAQ:092040) Is InterestingFor beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...Valuation Update With 7 Day Price Move • Mar 22Investor sentiment improved over the past weekAfter last week's 19% share price gain to ₩36,300, the stock trades at a trailing P/E ratio of 20.9x. Average trailing P/E is 54x in the Biotechs industry in South Korea. Total returns to shareholders of 7.7% over the past three years.분석 기사 • Mar 05Should Amicogen (KOSDAQ:092040) Be Disappointed With Their 24% Profit?Amicogen, Inc. ( KOSDAQ:092040 ) shareholders might be concerned after seeing the share price drop 14% in the last...Is New 90 Day High Low • Feb 24New 90-day low: ₩29,700The company is down 11% from its price of ₩33,400 on 26 November 2020. The South Korean market is up 17% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 7.0% over the same period.분석 기사 • Feb 15Is Amicogen (KOSDAQ:092040) A Risky Investment?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Is New 90 Day High Low • Feb 08New 90-day low: ₩31,700The company is down 5.0% from its price of ₩33,300 on 10 November 2020. The South Korean market is up 25% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 7.0% over the same period.분석 기사 • Jan 31What Kind Of Investors Own Most Of Amicogen, Inc. (KOSDAQ:092040)?Every investor in Amicogen, Inc. ( KOSDAQ:092040 ) should be aware of the most powerful shareholder groups...분석 기사 • Jan 14Could The Market Be Wrong About Amicogen, Inc. (KOSDAQ:092040) Given Its Attractive Financial Prospects?Amicogen (KOSDAQ:092040) has had a rough three months with its share price down 5.7%. However, stock prices are usually...분석 기사 • Dec 30Amicogen (KOSDAQ:092040) Is Growing Earnings But Are They A Good Guide?Statistically speaking, it is less risky to invest in profitable companies than in unprofitable ones. However...Valuation Update With 7 Day Price Move • Dec 30Investor sentiment improved over the past weekAfter last week's 15% share price gain to ₩38,400, the stock is trading at a trailing P/E ratio of 22.1x, up from the previous P/E ratio of 19.2x. This compares to an average P/E of 56x in the Biotechs industry in South Korea. Total returns to shareholders over the past three years are 68%.분석 기사 • Dec 15Is Now The Time To Put Amicogen (KOSDAQ:092040) On Your Watchlist?For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...분석 기사 • Nov 30Did You Miss Amicogen's (KOSDAQ:092040) 37% Share Price Gain?While Amicogen, Inc. (KOSDAQ:092040) shareholders are probably generally happy, the stock hasn't had particularly good...매출 및 비용 세부 내역Amicogen가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이KOSDAQ:A092040 매출, 비용 및 순이익 (KRW Millions)날짜매출순이익일반관리비연구개발비31 Dec 2541,981-29,96010,0797,44630 Sep 2587,966-63,42819,6158,90630 Jun 25117,721-49,63326,9749,76631 Mar 25150,247-52,96033,96311,10131 Dec 24173,605-52,79141,08812,60830 Sep 24155,739-35,70238,27212,63330 Jun 24158,984-36,90736,52213,36631 Mar 24155,881-30,70935,42213,21331 Dec 23159,904-23,28934,79913,78330 Sep 23164,246-29,42034,03814,51930 Jun 23160,012-28,64634,25614,04131 Mar 23152,966-36,63633,29913,67831 Dec 22144,296-47,22033,59612,43630 Sep 22139,504-39,81334,25811,64130 Jun 22124,834-61,07233,19611,85931 Mar 22123,766-3,13233,89611,54931 Dec 21124,8813,73333,79010,84330 Sep 21117,31733,20232,5089,72930 Jun 21122,41461,56932,0058,11131 Mar 21121,27439,19331,3416,75631 Dec 20115,85631,60431,1386,28230 Sep 20129,17133,39443,8205,02630 Jun 20120,53614,27243,1685,13231 Mar 20114,651-34,07443,8385,48731 Dec 19115,1818741,8215,37630 Sep 1990,8829,72825,6825,52430 Jun 1994,62021,42824,6675,24431 Mar 1991,33863,86721,5825,24531 Dec 1894,52240,16820,3125,18330 Sep 1899,01315,83419,4475,83230 Jun 1889,82214,60317,7825,56331 Mar 1886,089-3,39516,3655,12331 Dec 1773,665-4,60615,6244,77030 Sep 1772,07553315,9143,44030 Jun 1767,59433215,5223,18731 Mar 1766,193-62614,9842,63331 Dec 1668,9681,58914,2772,81130 Sep 1664,7821,63012,8993,10930 Jun 1657,4172,09811,7142,50431 Mar 1646,3543,2489,3432,47631 Dec 1532,4572,0666,3052,28830 Sep 1524,2634,8164,2671,67930 Jun 1526,6196,7743,2721,679양질의 수익: A092040 은(는) 현재 수익성이 없습니다.이익 마진 증가: A092040는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: A092040은 수익성이 없으며 지난 5년 동안 손실이 연평균 46.3% 증가했습니다.성장 가속화: 현재 수익성이 없어 지난 1년간 A092040의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: A092040은 수익성이 없어 지난 해 수익 성장률을 Biotechs 업계(32.2%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: A092040는 현재 수익성이 없으므로 자본 수익률이 음수(-28.51%)입니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YPharmaceuticals-biotech 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/21 10:20종가2026/05/21 00:00수익2025/12/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Amicogen, Inc.는 1명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관So-Eun ChoiLS Securities Co., Ltd.
Reported Earnings • Mar 25Full year 2024 earnings released: ₩961 loss per share (vs ₩584 loss in FY 2023)Full year 2024 results: ₩961 loss per share (further deteriorated from ₩584 loss in FY 2023). Revenue: ₩173.6b (up 8.6% from FY 2023). Net loss: ₩52.8b (loss widened 127% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 11% per year but the company’s share price has fallen by 38% per year, which means it is performing significantly worse than earnings.
분석 기사 • Dec 30Amicogen (KOSDAQ:092040) Is Growing Earnings But Are They A Good Guide?Statistically speaking, it is less risky to invest in profitable companies than in unprofitable ones. However...
공시 • Mar 11Amicogen, Inc., Annual General Meeting, Mar 31, 2026Amicogen, Inc., Annual General Meeting, Mar 31, 2026, at 10:00 Tokyo Standard Time. Location: conference room, 33, yeongudanji-ro 55beon-gil, yeonsu-gu, incheon South Korea
New Risk • Feb 26New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 29% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (14% average weekly change). Earnings have declined by 52% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (29% increase in shares outstanding). Market cap is less than US$100m (₩87.7b market cap, or US$61.5m).
New Risk • Feb 24New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 14% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (14% average weekly change). Earnings have declined by 52% per year over the past 5 years. Minor Risk Market cap is less than US$100m (₩69.6b market cap, or US$48.2m).
공시 • Feb 10Amicogen, Inc. has completed a Follow-on Equity Offering in the amount of KRW 17.373135 billion.Amicogen, Inc. has completed a Follow-on Equity Offering in the amount of KRW 17.373135 billion. Security Name: Common Stock Security Type: Common Stock Securities Offered: 14,925,374 Price\Range: KRW 1164
분석 기사 • Dec 22Investors Don't See Light At End Of Amicogen, Inc.'s (KOSDAQ:092040) Tunnel And Push Stock Down 33%Unfortunately for some shareholders, the Amicogen, Inc. ( KOSDAQ:092040 ) share price has dived 33% in the last thirty...
New Risk • Dec 22New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 52% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Market cap is less than US$100m (₩108.0b market cap, or US$73.0m).
공시 • Dec 20Amicogen, Inc. has filed a Follow-on Equity Offering in the amount of KRW 30.000002 billion.Amicogen, Inc. has filed a Follow-on Equity Offering in the amount of KRW 30.000002 billion. Security Name: Common Stock Security Type: Common Stock Securities Offered: 14,925,374 Price\Range: KRW 2010
New Risk • Dec 02New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩143.8b (US$97.9m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩44b free cash flow). Earnings have declined by 52% per year over the past 5 years. Minor Risk Market cap is less than US$100m (₩143.8b market cap, or US$97.9m).
New Risk • Nov 29New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₩44b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩44b free cash flow). Earnings have declined by 52% per year over the past 5 years.
분석 기사 • Sep 08The Market Doesn't Like What It Sees From Amicogen, Inc.'s (KOSDAQ:092040) Revenues YetWith a price-to-sales (or "P/S") ratio of 1.8x Amicogen, Inc. ( KOSDAQ:092040 ) may be sending very bullish signals at...
공시 • Aug 12Amicogen, Inc. announced that it has received KRW 7 billion in funding from BIFIDO Co., Ltd.On August 11, 2025, Amicogen, Inc. closed the transaction.
New Risk • Jul 17New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩25b free cash flow). Share price has been highly volatile over the past 3 months (12% average weekly change). Earnings have declined by 46% per year over the past 5 years.
분석 기사 • May 23Amicogen, Inc.'s (KOSDAQ:092040) Share Price Is Matching Sentiment Around Its RevenuesYou may think that with a price-to-sales (or "P/S") ratio of 1.3x Amicogen, Inc. ( KOSDAQ:092040 ) is definitely a...
Reported Earnings • Mar 25Full year 2024 earnings released: ₩961 loss per share (vs ₩584 loss in FY 2023)Full year 2024 results: ₩961 loss per share (further deteriorated from ₩584 loss in FY 2023). Revenue: ₩173.6b (up 8.6% from FY 2023). Net loss: ₩52.8b (loss widened 127% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 11% per year but the company’s share price has fallen by 38% per year, which means it is performing significantly worse than earnings.
공시 • Mar 12Amicogen, Inc., Annual General Meeting, Mar 27, 2025Amicogen, Inc., Annual General Meeting, Mar 27, 2025, at 10:00 Tokyo Standard Time. Location: conference room, 33, yeongudanji-ro 55beon-gil, yeonsu-gu, incheon South Korea
분석 기사 • Feb 17Is Amicogen (KOSDAQ:092040) Using Too Much Debt?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
분석 기사 • Jan 08Amicogen, Inc. (KOSDAQ:092040) Held Back By Insufficient Growth Even After Shares Climb 35%Amicogen, Inc. ( KOSDAQ:092040 ) shareholders are no doubt pleased to see that the share price has bounced 35% in the...
New Risk • Dec 23New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (3.7% operating cash flow to total debt). Earnings have declined by 44% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (9.4% average weekly change). Shareholders have been diluted in the past year (40% increase in shares outstanding).
공시 • Dec 12An undisclosed buyer agreed to acquire an unknown stake in Amicogen (China) Biopharm Co., Ltd. from Amicogen, Inc. (KOSDAQ:A092040) for KRW 54.7 billion.An undisclosed buyer agreed to acquire an unknown stake in Amicogen (China) Biopharm Co., Ltd. from Amicogen, Inc. (KOSDAQ:A092040) for KRW 54.7 billion on December 10, 2024. After completion of this ransaction, Amicogen, Inc. will hold 14.36% stake in Amicogen (China) Biopharm. Amicogen (China) Biopharm reported total assets of KRW 210.359 billion, total debt of KRW 95.656 billion, sales of KRW 84.911 billion and net income of KRW 8.074 billion as at September 30, 2024. The expected completion of the transaction is December 30, 2024.
New Risk • Dec 09New major risk - Financial positionThe company's debt is not well covered by operating cash flow. Operating cash flow to total debt ratio: 3.7% This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (3.7% operating cash flow to total debt). Earnings have declined by 44% per year over the past 5 years. Minor Risk Shareholders have been diluted in the past year (40% increase in shares outstanding).
New Risk • Dec 07New minor risk - Financial data availabilityLess than 3 years of financial data is available. This is considered a minor risk. If the company has been trading for less than 3 years, then it has not had the opportunity to establish a long-term track record. This makes it difficult for investors to assess the true growth potential, sustainability and resilience of the business under different economic conditions. Currently, the following risks have been identified for the company: Minor Risks Less than 3 years of financial data is available. Shareholders have been diluted in the past year (40% increase in shares outstanding).
공시 • Nov 23Enzynomics Co., Ltd. completed the acquisition of 37.32% stake in SKINMED Co., Ltd. from Amicogen, Inc. (KOSDAQ:A092040).Enzynomics Co., Ltd. agreed to acquire 37.32% stake in SKINMED Co., Ltd. from Amicogen, Inc. (KOSDAQ:A092040) for KRW 5.6 billion on November 15, 2024. A cash consideration of KRW 5.6 billion will be paid by Enzynomics for 2,360,714 shares. For the period ending December 31, 2023, SKINMED Co., Ltd. reported total revenue of KRW 6.07 billion and net loss of KRW 1.04 billion. As of December 31, 2023, SKINMED Co., Ltd. reported total debt of KRW 4.96 billion, total assets of KRW 11.22 billion and total common equity of KRW 6.26 billion. Enzynomics Co., Ltd. completed the acquisition of 37.32% stake in SKINMED Co., Ltd. from Amicogen, Inc. (KOSDAQ:A092040) on November 19, 2024.
분석 기사 • Nov 11Revenues Working Against Amicogen, Inc.'s (KOSDAQ:092040) Share PriceAmicogen, Inc.'s ( KOSDAQ:092040 ) price-to-sales (or "P/S") ratio of 1.5x might make it look like a strong buy right...
공시 • Oct 30+ 1 more updateAmicogen, Inc. announced that it has received KRW 4 billion in funding from Kiwoom Securities Co., Ltd.On October 29, 2024 Amicogen, Inc. closed the transaction.
New Risk • Sep 17New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Shareholders have been diluted in the past year (40% increase in shares outstanding).
분석 기사 • Jun 27Little Excitement Around Amicogen, Inc.'s (KOSDAQ:092040) Revenues As Shares Take 27% PoundingTo the annoyance of some shareholders, Amicogen, Inc. ( KOSDAQ:092040 ) shares are down a considerable 27% in the last...
분석 기사 • Jun 19Does Amicogen (KOSDAQ:092040) Have A Healthy Balance Sheet?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...
분석 기사 • Mar 21Amicogen, Inc. (KOSDAQ:092040) Held Back By Insufficient Growth Even After Shares Climb 39%Amicogen, Inc. ( KOSDAQ:092040 ) shares have had a really impressive month, gaining 39% after a shaky period...
New Risk • Mar 21New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (0.1x net interest cover). Earnings have declined by 48% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (8.3% average weekly change). Shareholders have been diluted in the past year (39% increase in shares outstanding).
New Risk • Dec 28New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 39% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (0.1x net interest cover). Earnings have declined by 48% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (8.7% average weekly change). Shareholders have been diluted in the past year (39% increase in shares outstanding).
New Risk • Nov 24New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). Earnings have declined by 44% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (8.6% average weekly change).
공시 • Jul 19+ 1 more updateAmicogen, Inc. announced that it expects to receive KRW 40 billion in fundingAmicogen, Inc. announced a private placement of series 3 unregistered nonguaranteed private convertible bond for gross proceeds of KRW 40,000,000,000 on July 18, 2022. The bonds will mature on July 20, 2027. The bonds are convertible into 1,622,520 common shares at a price of KRW 24,653 per share. The conversion period is from July 20, 2023 to June 20, 2027. The payment date is July 20, 2022. The transaction has been approved by the board of directors.
Valuation Update With 7 Day Price Move • Jan 27Investor sentiment deteriorated over the past weekAfter last week's 15% share price decline to ₩24,850, the stock trades at a trailing P/E ratio of 14.6x. Average trailing P/E is 33x in the Biotechs industry in South Korea. Total loss to shareholders of 34% over the past three years.
공시 • Sep 03Amicogen, Inc. announced that it has received KRW 22.2724863 billion in funding from Lysando AGOn September 2, 2021, Amicogen, Inc. closed the transaction.
공시 • Jul 23Amicogen, Inc. (KOSDAQ:A092040) agreed to acquire a 30% stake in BIFIDO Co., Ltd (KOSDAQ:A238200) from a group of shareholders for KRW 60.1 billion.Amicogen, Inc. (KOSDAQ:A092040) agreed to acquire a 30% stake in BIFIDO Co., Ltd (KOSDAQ:A238200) from a group of shareholders for KRW 60.1 billion on July 21, 2021. Under the term, Amicogen will acquire 2.45 million shares of BIFIDO at KRW 24,500 per shares. Amicogen will pay 20% of the consideration amounting to KRW 12.02 billion on July 21, 2021 as the down payment or first payment, second payment or the interim payment which is 30% of the consideration amounting to KRW 18.04 billion will be paid on August 20, 2021 and the balance which is 50% of the consideration amounting to KRW 30.06 billion will be paid on October 20, 2021. Post completion, Amicogen will hold 30% stake in BIFIDO. The transaction was resolved by the board of directors of Amicogen on July 21, 2021. The transaction is expected to close on October 21, 2021.
공시 • Jul 15Amicogen, Inc. announced that it expects to receive KRW 22.2724863 billion in funding from Lysando AGAmicogen, Inc. announced a private placement of 532,198 shares at a price of KRW 41,850 per share for gross proceeds of KRW 22,272,486,300 on July 14, 2021. The transaction will include participation from Lysando AG. The transaction is expected to close on August 20, 2021. The securities to be issued will have a hold period of 1 year. The transaction was approved by the board of directors of the company. The company will received funding through third party allocation.
공시 • Jul 01Amicogen, Inc. announced that it has received KRW 50 billion in fundingOn June 29, 2021, Amicogen, Inc. closed the transaction.
공시 • Jun 24Amicogen, Inc. announced that it expects to receive KRW 50 billion in funding from Samsung Securities Co., Ltd. and other investorsAmicogen, Inc. (KOSDAQ:A092040) announced a private placement of series 1 unregistered nonguaranteed private convertible bond for gross proceeds of KRW 50,000,000,000 on June 23, 2021. The transaction will include participation from Samsung Securities Co., Ltd. (KOSE:A016360) for KRW 46,000,000,000, and Small and Medium Business Banks for the rest. The bonds will mature on June 28, 2026. The bonds are convertible into 1,203,311 common shares at a price of KRW 41,552 per share. The conversion period is from June 29, 2022 to May 29, 2026. The payment date is June 29, 2021. The transaction has been approved by the board.
분석 기사 • Mar 23With EPS Growth And More, Amicogen (KOSDAQ:092040) Is InterestingFor beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...
Valuation Update With 7 Day Price Move • Mar 22Investor sentiment improved over the past weekAfter last week's 19% share price gain to ₩36,300, the stock trades at a trailing P/E ratio of 20.9x. Average trailing P/E is 54x in the Biotechs industry in South Korea. Total returns to shareholders of 7.7% over the past three years.
분석 기사 • Mar 05Should Amicogen (KOSDAQ:092040) Be Disappointed With Their 24% Profit?Amicogen, Inc. ( KOSDAQ:092040 ) shareholders might be concerned after seeing the share price drop 14% in the last...
Is New 90 Day High Low • Feb 24New 90-day low: ₩29,700The company is down 11% from its price of ₩33,400 on 26 November 2020. The South Korean market is up 17% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 7.0% over the same period.
분석 기사 • Feb 15Is Amicogen (KOSDAQ:092040) A Risky Investment?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Is New 90 Day High Low • Feb 08New 90-day low: ₩31,700The company is down 5.0% from its price of ₩33,300 on 10 November 2020. The South Korean market is up 25% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 7.0% over the same period.
분석 기사 • Jan 31What Kind Of Investors Own Most Of Amicogen, Inc. (KOSDAQ:092040)?Every investor in Amicogen, Inc. ( KOSDAQ:092040 ) should be aware of the most powerful shareholder groups...
분석 기사 • Jan 14Could The Market Be Wrong About Amicogen, Inc. (KOSDAQ:092040) Given Its Attractive Financial Prospects?Amicogen (KOSDAQ:092040) has had a rough three months with its share price down 5.7%. However, stock prices are usually...
분석 기사 • Dec 30Amicogen (KOSDAQ:092040) Is Growing Earnings But Are They A Good Guide?Statistically speaking, it is less risky to invest in profitable companies than in unprofitable ones. However...
Valuation Update With 7 Day Price Move • Dec 30Investor sentiment improved over the past weekAfter last week's 15% share price gain to ₩38,400, the stock is trading at a trailing P/E ratio of 22.1x, up from the previous P/E ratio of 19.2x. This compares to an average P/E of 56x in the Biotechs industry in South Korea. Total returns to shareholders over the past three years are 68%.
분석 기사 • Dec 15Is Now The Time To Put Amicogen (KOSDAQ:092040) On Your Watchlist?For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...
분석 기사 • Nov 30Did You Miss Amicogen's (KOSDAQ:092040) 37% Share Price Gain?While Amicogen, Inc. (KOSDAQ:092040) shareholders are probably generally happy, the stock hasn't had particularly good...